Increased recombinant activated factor VII use and need for surgical reexploration following a switch from aprotinin to epsilon-aminocaproic acid in infant cardiac surgery

Journal of Clinical Anesthesia

Volumn 26, Issue 3, 2014, Pages 204-211

  Scott, John P ^a,b   Costigan, Daniel J ^a,b   Hoffman, George M ^a,b   Simpson, Pippa M ^a   Dasgupta, Mahua ^a   Punzalan, Rowena ^a,b   Berens, Richard J ^a,b   Tweddell, James S ^a,b   Stuth, Eckehard A E ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

Author keywords

Antifibrinolytic therapy; Aprotinin; Cardiac surgery, pediatric; Epsilon aminocaproic acid; Infant cardiac surgery; Perioperative bleeding; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; APROTININ; FRESH FROZEN PLASMA; HEPARIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLOOD VOLUME; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CRYOPRECIPITATE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; HEART SURGERY; HEMOSTASIS; HUMAN; INFANT; KIDNEY FAILURE; LOADING DRUG DOSE; MEDICAL RECORD REVIEW; OPERATIVE BLOOD LOSS; PEDIATRIC SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; THROMBOSIS; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; COMPARATIVE STUDY; NEWBORN; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; HEMOSTATICS; HUMANS; INFANT; INFANT, NEWBORN; PLATELET TRANSFUSION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84901652434     PISSN: 09528180     EISSN: 18734529     Source Type: Journal    
DOI: 10.1016/j.jclinane.2013.10.015     Document Type: Article

References (32)

1. M. Levi, M.E. Cromheecke, and E. de Jonge et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints Lancet 354 9194 1999 1940 1947
2. H. Mössinger, W. Dietrich, S.L. Braun, M. Jochum, H. Meisner, and J.A. Richter High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery Ann Thorac Surg 75 2003 430 437
3. M.P. Eaton Antifibrinolytic therapy in surgery for congenital heart disease Anesth Analg 106 2008 1087 1100
4. N. Tabuchi, J. De Haan, P.W. Boonstra, R.C. Huet, and W. Van Oeveren Aprotinin effect on platelet function and clotting during cardiopulmonary bypass Eur J Cardiothorac Surg 8 1994 87 90
5. P.M. Mannucci Hemostatic drugs N Engl J Med 339 1998 245 253
6. C.F. Mojcik, and J.H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann Thorac Surg 71 2001 745 754
7. T.A. Khan, C. Bianchi, P. Voisine, J. Sandmeyer, J. Feng, and F.W. Sellke Aprotinin inhibits protease-dependent platelet aggregation and thrombosis Ann Thorac Surg 79 2005 1545 1550
8. D.A. Fergusson, P.C. Hébert, and C.D. Mazer et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331
9. S. Schneeweiss, J.D. Seeger, J. Landon, and A.M. Walker Aprotinin during coronary-artery bypass grafting and risk of death N Engl J Med 358 2008 771 783
10. A.D. Shaw, M. Stafford-Smith, and W.D. White et al. The effect of aprotinin on outcome after coronary-artery bypass grafting N Engl J Med 358 2008 784 793
11. T. Breuer, K. Martin, and M. Wilhelm et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery Eur J Cardiothorac Surg 35 2009 167 171
12. D.T. Mangano, Y. Miao, and A. Vuylsteke et al; Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery JAMA 297 2007 471 479
13. V. McMullan, and R.P. Alston III Aprotinin and cardiac surgery: a sorry tale of evidence misused Br J Anaesth 110 2013 675 678
14. D.G. Ririe, R.L. James, and J.J. O'Brien et al. The pharmacokinetics of epsilon-aminocaproic acid in children undergoing surgical repair of congenital heart defects Anesth Analg 94 2002 44 49
15. R.D. Jaquiss, N.S. Ghanayem, M.C. Zacharisen, K.A. Mussatto, J.S. Tweddell, and S.B. Litwin Safety of aprotinin use and re-use in pediatric cardiothoracic surgery Circulation 106 12 Suppl 1 2002 190 194
16. F. Lacour-Gayet, D. Clarke, J. Jacobs Aristotle Committee The Aristotle score: a complexity-adjusted method to evaluate surgical results Eur J Cardiothorac Surg 25 2004 911 924
17. G. Wernovsky, D. Wypij, and R.A. Jonas et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest Circulation 92 1995 2226 2235
18. P.H. Westfall, R. Tobias, D. Rom, R. Wolfinger, and Y. Hochberg Multiple Comparisons and Multiple Tests using the SAS System 1999 SAS Institute, Inc., Books by Users Cary (NC)
19. Uber WE, Toole JM, Stroud MR, et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg 2011;141:1469,1477.e2.
20. K. Martin, R. Gertler, and H. Liermann et al. Switch from aprotinin to epsilon-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery Br J Anaesth 107 2011 934 939
21. N.S. Wilder, M.N. Kavarana, T. Voepel-Lewis, T. Paugh, T. Lee, and R.G. Ohye Efficacy and safety of aprotinin in neonatal congenital heart operations Ann Thorac Surg 92 2011 958 963
22. S.K. Pasquali, J.S. Li, and X. He et al. Comparative analysis of antifibrinolytic medications in pediatric heart surgery J Thorac Cardiovasc Surg 143 2012 550 557
23. K. Martin, R. Gertler, and M. MacGuill et al. Replacement of aprotinin by epsilon-aminocaproic acid in infants undergoing cardiac surgery: consequences for blood loss and outcome Br J Anaesth 110 2013 615 621
24. E.M. Graham, A.M. Atz, and J. Gillis et al. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery J Thorac Cardiovasc Surg 143 2012 1069 1076
25. G. Leyvi, O. Nelson, and A. Yedlin et al. A comparison of the effect of aprotinin and epsilon-aminocaproic acid on renal function in children undergoing cardiac surgery J Cardiothorac Vasc Anesth 25 2011 402 406
26. P.H. Tsau, F.A. Arabia, B. Toporoff, V. Paramesh, G.K. Sethi, and J.G. Copeland Positive panel reactive antibody titers in patients bridged to transplantation with a mechanical assist device: risk factors and treatment ASAIO J 44 1998 M634 M637
27. M.J. Unsworth-White, A. Herriot, and O. Valencia et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality Ann Thorac Surg 59 1995 664 667
28. K.A. O'Connell, J.J. Wood, R.P. Wise, J.N. Lozier, and M.M. Braun Thromboembolic adverse events after use of recombinant human coagulation factor VIIa JAMA 295 2006 293 298
29. M. Ponschab, G. Landoni, and G. Biondi-Zoccai et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis J Cardiothorac Vasc Anesth 25 2011 804 810
30. M.J. Moulton, L.L. Creswell, M.E. Mackey, J.L. Cox, and M. Rosenbloom Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations J Thorac Cardiovasc Surg 111 1996 1037 1046
31. A. Michalopoulos, G. Tzelepis, U. Dafni, and S. Geroulanous Determinants of hospital mortality after coronary artery bypass grafting Chest 115 1999 1598 1603
32. N. Pichon, F. Bellec, and S. Sekkal et al. Fatal thrombotic event after infusion of recombinant activated factor VII after cardiac surgery J Thorac Cardiovasc Surg 136 2008 220 221